RxDoctor Payments Data

Gregorio Joel Castillo, MD

Internal Medicine · El Paso, TXNPI 1184695488

Payments from drug & device makers

$1,939in general payments, 2019–2025

Across 111 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$504
  • GSK$273
  • Boehringer Ingelheim$210
  • Sanofi-aventis U.S. LLC$154
  • Novo Nordisk$110
  • Amarin Pharma, Inc.$87
  • plus $602 from 13 others

What the payments were for

  • Food & beverage$1,939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,939 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$21,197
Medicare patients
99
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$184,541
OzempicSemaglutide71$95,586
EliquisApixaban49$73,941
JanuviaSitagliptin Phosphate40$52,282
XareltoRivaroxaban31$44,867
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$43,511
MounjaroTirzepatide27$38,568
FarxigaDapagliflozin Propanediol37$36,258
Bydureon BciseExenatide Microspheres15$29,223
TrulicityDulaglutide15$27,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,727
Tresiba Flextouch U-100Insulin Degludec17$18,166
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$16,185
Breo ElliptaFluticasone/Vilanterol18$15,920
BrilintaTicagrelor14$13,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$210$184,541154 claims
Novo NordiskOzempic$110$95,58671 claims
PfizerEliquis$70$73,94149 claims
MerckJanuvia$54$52,28240 claims
AstraZenecaFarxiga, Brilinta$504$49,27251 claims
Johnson & JohnsonXarelto$42$44,86731 claims
GSKTrelegy Ellipta, Breo Ellipta$273$34,64732 claims
Sanofi-aventis U.S. LLCLantus$154$6,86623 claims
AbbVieSynthroid$18$1,76039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →